The many faces of c-MYC

Area of Science:

• Molecular Biology
• Oncology
• Endocrinology

Background:

• The proto-oncogene c-MYC regulates critical cellular processes including growth, proliferation, differentiation, and apoptosis.
• Aberrant c-MYC expression (oncogenic c-MYC) is a hallmark of numerous human cancers, often correlating with poor patient prognosis.
• Emerging research implicates c-MYC in the pathogenesis of diabetes through its role in the loss and dysfunction of insulin-producing beta cells.

Purpose of the Study:

• To explore the multifaceted roles of c-MYC in both cancer and diabetes.
• To investigate the potential of targeting c-MYC as a therapeutic strategy for diseases characterized by deregulated cell proliferation and apoptosis.
• To highlight the utility of regulatable transgenic mouse models in dissecting the in vivo functions of oncogenes like c-MYC.

Main Methods:

• Review and synthesis of existing literature on c-MYC function in physiological and pathological contexts.
• Analysis of data from regulatable transgenic mouse models to understand c-MYC's role in disease development.
• Evaluation of emerging gene-targeting strategies aimed at interfering with c-MYC expression or activity.

Main Results:

• c-MYC's dual role in promoting proliferation and inducing apoptosis suggests complex contributions to disease pathology.
• Transgenic mouse models provide valuable insights into the in vivo effects of c-MYC deregulation.
• Preclinical studies demonstrate promising results for gene-targeting approaches against c-MYC in vitro and in vivo.

Conclusions:

• c-MYC is a significant factor in cancer and potentially in diabetes, acting through both proliferation and apoptosis pathways.
• Targeting c-MYC presents a promising avenue for novel cancer therapies.
• Further research and development of gene-targeting strategies are warranted to fully exploit c-MYC as a therapeutic target.